LCM
RXRX icon

LCM Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

LCM Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.8K Hold
12,000
– – 0.02% 107
2025
Q4 		$49.1K Hold
12,000
– – 0.02% 108
2025
Q3 		$58.6K Hold
12,000
– – 0.03% 104
2025
Q2 		$60.7K Hold
12,000
– – 0.03% 103
2025
Q1 		$63.5K Buy
+12,000
New +$87.5K 0.04% 99

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LCM Capital Management's RXRX Position: Q1 2026 in Review

LCM Capital Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 12,000 shares worth $36.8K. The position accounts for 0.02% of the portfolio, ranked #107.

LCM Capital Management first reported a position in RXRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $63.5K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • LCM Capital Management held 12,000 shares of Recursion Pharmaceuticals worth $36.8K as of Q1 2026.
  • LCM Capital Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up 0.02% of LCM Capital Management's portfolio in Q1 2026, its #107 holding.
  • LCM Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • LCM Capital Management's Recursion Pharmaceuticals position peaked at $63.5K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on LCM Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.